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Due to the increasing incidence of cancer diagnoses and lack of validated screenings for most 
types of cancer, cancer researchers continue to look for ways to improve cancer screening 
particularly for cancers that are difficult to detect early. One early detection technology being 
researched is blood-based testing looking for the presence of DNA from tumor cells, circulating 
tumor DNA (ctDNA). With any new cancer screening test there is a need to understand how 
participants respond, socially and psychologically, to abnormal results. Participants in 
Geisinger’s DETECT study of a ctDNA test, CancerSEEK, who received positive ctDNA blood 
test results and opted to undergo a PET-CT scan, were interviewed to assess psychosocial 
outcomes of true positive and false positive blood test results. Qualitative data analysis of 
interviews of participants with true positive and false positive results using Atlas.ti identified 16 
major themes. Results of the qualitative analysis revealed some differences between the negative 
and positive PET-CT groups. However, most participants, in both groups, reported a positive 
experience with the DETECT study and would recommend it to others. Results of the study 
suggest that the psychosocial outcomes associated with ctDNA-based cancer screening tests 
should continue to be explored in-depth to provide sufficient evidence for future usage.   
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Cancer is defined as uncontrolled cell growth; malignant cells grow and divide rapidly 
leading to a diagnosis that is either localized or metastasized throughout tissues of the body. 
Cancer cells have six main features that distinguish them from healthy cells: independence of 
external growth signals, insensitivity to external anti-growth signals, ability to avoid apoptosis, 
ability to duplicate indeterminately, ability to activate angiogenesis and vascularize, and ability 
to attack tissues and create secondary tumors (Hanahan & Weinberg, 2000). Cancer is the second 
leading cause of death in the United States and each year the number of diagnoses and deaths 
increase worldwide. The chance to develop cancer depends on an individual’s exposure, medical 
history, and genetic predisposition. The lifetime risk for a male to develop an invasive cancer is 
42%, whereas for women it is 38%. While there has been a consistent decline in the death rate 
from cancer, by 1.4% in women and 1.8% in men annually from 2007 to 2016, it remains a 
serious public health concern. An estimated 1.7 million new cancer cases will arise in 2019 alone 
(Siegel et al., 2019).    
Recommended Screening Guidelines, Risk Reduction Benefits, and Psychosocial Outcomes 
for Existing Cancer Screening Modalities 
Several screening tests have been found to reduce cancer morbidity and mortality rates. 
Many organizations provide evidence-based recommendations about cancer screenings; 
however, these recommendations vary, making these preventive services more difficult for 
patients and providers to navigate. It is important to assess the societal and individual impact of 
these screenings in an effort to promote adherence. Adherence to screening recommendations 
provides the benefit of detecting cancer at earlier stages; nonadherence diminishes this benefit. 
When considering reasons for nonadherence, psychosocial harms of the screenings should be 
 7 
explored. There is significant evidence of anxiety produced by cancer screening methods, 
especially when false positive results are the outcome (Brodersen & Siersma, 2013; Lipkus et al., 
2000; Toft et al., 2019). The recommended screening guidelines, risk reduction benefits, and 
associated psychosocial harms are outlined for the following cancers: breast, colorectal, and 
lung.  
Breast Cancer  
The United States Preventive Services Task Force (USPSTF) recommends biennial 
mammography screening for women aged 50 to 74 years to maximize screening benefits. The 
USPSTF specifies that these guidelines are appropriate for average-risk women, who are at the 
general population risk to develop cancer. Prior to this, between ages 40 to 49, the decision to 
begin screening is on an individual basis. Lastly, the USPSTF provides no recommendations for 
screening women aged 75 and older (Siu et al., 2016). In contrast with the USPSTF, the National 
Comprehensive Cancer Network (NCCN) and other professional societies recommend annual 
mammography screening beginning at age 40 in average-risk women. Women who begin 
mammography screening in their 40s benefit from a reduction in breast cancer mortality. Early 
detection of breast cancer also leads to less aggressive treatment regimens and associated 
morbidities. The screening benefits outweigh the psychosocial harms associated with 
mammography, like anxiety due to false positive results and overdiagnoses. NCCN also 
addresses screening recommendations for women at increased risk of breast cancer (NCCN 
Guidelines Version 1.2019 Breast Cancer Screening and Diagnosis, 2019). Notably, the USPSTF 
does not provide screening recommendations for this group of high-risk women. 
Women receiving false positive results report negative psychosocial harms such as 
breast-cancer specific worry, concern impacting mood and daily routines, lower cognitive 
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functioning, lower energy levels, and increased depression. Additionally, follow-up testing with 
negative results can cause persistent anxiety, continued breast-cancer specific worry, and distress 
for patients (Nelson et al., 2016). One study evaluated 12 psychosocial outcomes among 454 
women with abnormal findings on mammography screening, using the Consequences of 
Screening in Breast Cancer Questionnaire. For every woman recruited with an abnormal finding, 
either true or false positive, two were enrolled that received normal mammogram screening 
results. Women with false positive results reported changes in existential values and inner 
calmness which were equivalent to responses reported by women with a diagnosis of breast 
cancer. In addition, women continuing to receive false positive results post-cancer diagnosis 
reported more negative psychosocial harms than women with normal mammogram screening 
results (Brodersen & Siersma, 2013).     
Colorectal Cancer  
To reduce colorectal cancer incidence and mortality, the USPSTF recommends screening 
in average-risk adults starting at age 50 years and continuing until age 75 years. The decision to 
screen for colorectal cancer in adults aged 76 to 85 is an individual one. Screening strategies 
include stool-based, direct visualization and serology tests, each with unique advantages and 
limitations (US Preventive Services Task Force, 2016). NCCN recommends starting screening 
earlier in adults at increased risk due to family history of cancer or pathogenic variants in 
colorectal cancer susceptibility genes. Shorter screening intervals are recommended for those at 
increased risk, compared to average-risk individuals who present for colonoscopy every 5-10 
years (NCCN Guidelines Version 2.2019 Colorectal Cancer Screening, 2019).  
Reported harms include unnecessary invasive follow-up testing for patients at low-risk 
and increased rates of anxiety, discomfort, and morbidity (US Preventive Services Task Force, 
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2016). One study assessed the psychosocial harms of receiving false positive screening results 
from an immunochemical fecal occult blood test (iFOBT), by interviewing 16 participants about 
their false positive results. Four main themes emerged: anxiety, discomfort, different self-
perception/behavior, and views on active participation in screening. False positive results led to 
prolonged feelings of anxiety among some participants, resulting in an increase in existing 
anxiety and psychological impairments. Individuals may feel discomfort during a screening 
procedure, their self-perception may change upon experiencing the process, and they may 
demonstrate hesitancy towards diagnostic screening methods in the future (Toft et al., 2019).    
Lung Cancer  
The USPSTF recommends annual low-dose computed tomography (LDCT) for 
individuals who have a 30 pack-year smoking history and currently smoke or have quit within 
the past 15 years, and are aged 55 to 80. Annual LDCT screening serves as a benefit for high-risk 
individuals and can prevent lung cancer-related mortality. Lung cancer screening can be 
associated with negative psychosocial outcomes due to false positive results, false negative 
results, incidental findings, overdiagnosis, and increased radiation exposure leading to cancer 
(Moyer et al., 2014).        
NCCN recommends LDCT testing after performing extensive risk assessment and 
categorizing risk status (high, moderate, or low-risk). Benefits of LDCT testing include 
decreased lung cancer mortality and discovery of other crucial health risks. A major benefit 
suggests an increase in quality of life by pursuing lung cancer screening, leading to the 
following: less morbidity related to the disease and treatment, aiding in a healthy lifestyle, and 
lessening anxiety/psychosocial harms. Psychosocial harms noted by NCCN include a decrease in 
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quality of life and anxiety of test findings (NCCN Guidelines Version 1.2020 Lung Cancer 
Screening, 2020).  
Future Directions for Cancer Screening with ctDNA  
Of the early detection technologies being researched, one of increasing interest is a 
blood-based testing looking for the presence of DNA from tumor cells. In contrast to many 
current cancer screenings, ctDNA-based screening offers an opportunity to screen for multiple 
cancers at once, including cancers for which no standard-of-care screenings exist, such as 
pancreatic and ovarian cancer. While a benefit of ctDNA-based cancer screening is that it is 
minimally invasive, requiring only a blood test, the psychosocial outcomes of abnormal ctDNA 
screening are unknown. As with any new screening modality, investigation into the psychosocial 
outcomes of abnormal results is important in understanding what may influence adherence, how 
it should be implemented clinically, and how it could positively or negatively impact care. 
Historical Background of ctDNA 
Documentation of the presence of circulating tumor cells goes back to the late 1800s 
when it was first observed in the blood of cancer patients (Neumann et al., 2018). Further 
evidence of the possibility of tumor DNA circulating in the blood came from a 1977 study 
comparing the level of free DNA in the serum of patients with different types of cancers to study 
participants without cancer (Leon et al., 1977). It was found that the levels of free DNA were 
increased in patients with cancer as compared to those without cancer; further differentiation 
found that those with metastatic cancers had significantly higher free DNA levels than those 
whose cancer was in situ. Significant decreases in the free DNA levels were found in the cancer 
patients who saw clinical improvements, like reduced tumor size, compared to patients who did 
not respond to cancer treatments and whose DNA levels were maintained throughout the study. 
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While the source of the additional free DNA was not fully understood in the study, the 
correlation of free DNA levels with the presence of cancer was indicative of some contribution 
of the tumor DNA to free DNA levels (Leon et al., 1977). More recently, expanded use of cell-
free DNA (cfDNA) for prenatal screening provided further evidence of tumor DNA circulating 
in the bloodstream through cfDNA results that were discordant with the fetal karyotype. The 
discordance was explained by the presence of maternal malignancy during pregnancy (Bianchi et 
al., 2015).  
Liquid Biopsy 
A liquid biopsy is the analysis of tumor-derived components found in the bloodstream; 
these components include a combination of whole circulating tumor cells (CTCs), circulating 
tumor DNA (ctDNA), RNA, proteins, and lipids that are shed from a tumor as apoptosis occurs 
(Palmirotta et al., 2018). The CTCs component of liquid biopsy are a stable, viable group of cells 
that can be purified from blood or particles on the surface of cells that differentiate them from 
typical blood cells. The ctDNA component is derived from lysed CTCs and consists of tiny 
fragments of free nucleic acids no longer associated with a cell (Olivi et al., 2014). Since the 
initial evidence of tumor analytes circulating in the blood, the use of liquid biopsy technology to 
detect these analytes has expanded to possibly become a fast, noninvasive, and low cost way of 
detecting cancer and monitoring disease status in response to treatment. It is believed that liquid 
biopsy circumvents challenges from biopsy of inaccessible tumors and biopsies that do not give a 
comprehensive picture of the tumor make up given metastasis or heterogeneity throughout the 
tumor tissue (Neumann et al., 2018). Proof of principle of how ctDNA works was established in 
a 2018 study done by Cohen et al., that used the ctDNA liquid biopsy, CancerSEEK, to 
successfully detect 70% of cancers that had already been clinically diagnosed. The specificity of 
 12 
this liquid biopsy was more than 99% across the eight cancer types that it was used to confirm 
diagnosis in. 
Benefits and Limitations of ctDNA Testing 
ctDNA analysis has the potential to address a limitation of traditional tumor tissue biopsy 
- the oversight of possible driver mutations given the limited scope of biopsy and the 
heterogeneity of tumor tissue. This limitation results in a lack of information on the tumor 
profile. There is also the limitation of tumor tissue not always being accessible for biopsy or 
metastasis making a biopsy of all tumor tissue difficult (Stewart et al., 2018). Potential areas of 
application for ctDNA include tumor diagnosis to detect residual tumor after surgery, cancer 
treatment response and follow-up, and the molecular evolution of tumors resistant to treatment 
(Neumann et al., 2018). Despite these benefits, some studies have shown a rate of discordance 
between ctDNA assays and tumor testing. This could be the result of what cells are released from 
the tumor, where the tumor is, what barriers are present that prevent cells from entering the 
circulatory system and insufficient amounts of ctDNA being present in the blood sample. What 
tumor tissue testing shows, that ctDNA assays can fail to reveal, is a full picture of new cell 
variants within the tumor (Merker et al., 2018). Early detection of cancer is complicated with 
liquid biopsy by the mutation load being minimal or below the level of detection in early cancer 
stages. The proportion of ctDNA found in a blood sample is correlated to the tumor size; at early 
stages, when the tumor is small, the percentage of ctDNA present in the blood will be limited 
(Stewart et al., 2018). In early stage cancer, ctDNA can make up only 1% of cfDNA but that can 
increase to 40% in late stage cancer (Neumann et al., 2018). There are also limitations with the 
inability of liquid biopsy to determine the location of origin of the cancer (Cohen et al., 2018). 
Psychosocial considerations 
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While there is limited data on the psychosocial impact of using ctDNA and liquid biopsy 
for cancer screening, there is significant evidence of the negative effect of other screening 
methods when false positive results are the outcome (Brodersen & Siersma, 2013; Lipkus et al., 
2000; Toft et al., 2019). As part of understanding the clinical utility of ctDNA for screening, is a 
need for research into the psychosocial implications of screening. It is reasonable to suspect that 
different psychosocial effects may be present that are not seen in other screening methods. This 
is due to the limitation of liquid biopsy not being able to determine the location of origin of the 
cancer and the often further advanced stage of cancer that ctDNA is able to be detected. Further 
research into these areas could shed more light onto the utility and impact of this cancer 
detection technology. 
MATERIALS AND METHODS  
Sample Population 
Study participants were recruited from among participants in Geisinger’s DETECT 
(Detecting Cancers Earlier Through Elective Mutation-Based Blood Collection and Testing) 
research study. Inclusion criteria for DETECT study participants included women, ranging in age 
from 65-76, with no prior personal history of cancer. Of the DETECT participants, 97% are of 
Caucasian ancestry. Participants were from within the Geisinger catchment area, which covers 
central Pennsylvania.  
Within the DETECT study, participants initially gave six tubes of blood. ctDNA and 
cancer biomarkers were analyzed using a “research marker panel test,” called CancerSEEK. 
Participants in the DETECT study who received two consecutive positive blood test results were 
contacted by the DETECT study genetic counselor with the result disclosure and 
recommendation to have a follow-up PET-CT. Following the PET-CT, patient results were 
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disclosed by a DETECT study physician, either an oncologist or primary care physician (A. M. 
Lennon et al., 2020). DETECT study participants who opted to undergo a PET-CT scan were 
eligible for participation in this qualitative study. A list of DETECT participants who had a PET-
CT was provided by the DETECT research study team. 
Procedures 
The DETECT study used the CancerSEEK blood test to interrogate the blood samples, 
from each participant, for 16 genes associated with cancer and levels of 11 protein markers, that 
can be elevated in individuals with cancer. CancerSEEK is expected to detect multiple cancer 
types, including pancreatic, ovarian, esophageal, liver, lung, breast, colorectal and stomach 
cancer. Participants were informed that their results might be used for research purposes beyond 
the DETECT research study.  
Qualitative interviews, using an investigator-created interview guide informed by 
previous research on psychosocial outcomes of cancer screening tests, were conducted with 
eligible participants to assess psychosocial outcomes of having a positive ctDNA test. The 
interview guide began with general consent for participation, as well as consent for audio 
recording, and usage of data for research purposes in accordance with the study IRB. Interviews 
were conducted until saturation of responses was reached. There were five attempts to reach 
eligible participants before they were excluded from the study. Participant data were de-
identified and stored with each participant interview case number for reference. All participant 
transcripts and audio recordings were saved on a Geisinger-protected desktop and were uploaded 
into the qualitative analysis program Atlas.ti. Qualitative analysis was conducted to assess 
participant views and psychosocial outcomes associated with a ctDNA-based cancer screening 
test. This study received an exemption from the Sarah Lawrence College Institutional Review 
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Board (IRB) in October 2019 along with approval from the Geisinger Health System IRB in 
April 2019.  
Measures 
The qualitative interview guide consisted of 9 stem questions, each followed by 0-10 
probes to obtain additional nuance. Stem questions were aimed at assessing participants’ 
rationale for joining the study, initial concerns regarding the possibility of detecting cancer, 
emotional response and coping strategies after the results of the CancerSEEK blood test and 
PET-CT scan, as well as response to discordant results (i.e., positive CancerSEEK followed by 
negative PET-CT), when applicable, previous cancer screening medical behaviors, and overall 
DETECT study satisfaction. Probe questions were aimed at gaining a better understanding of 
how participants coped with results, the negative and positive psychosocial outcomes they 
experienced, and their perception on the utility of the CancerSEEK blood test. Each participant 
was asked the 9 stem questions; probes were asked at the discretion of the interviewer based on 
the need for deeper or more comprehensive reflection.  
Analysis 
The codebook was created with the goal of identifying psychosocial themes that may 
have been present during the participants’ contemplation of DETECT study participation, 
discovery of the CancerSEEK blood test results, discovery of PET-CT results, and post PET-CT 
experience. Themes and ideas stated in the interviews were identified as codes for the codebook. 
Codes were contributed by both study coders to capture the full range of psychosocial themes 
and emotions described by study participants. The codes are organized by major themes (Table 
1) which allowed the coders to capture data relating to the most relevant psychosocial 
experiences expressed throughout the study. The codebook was established by consensus and 
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reviewed by the research supervisor. The final codebook contained 76 codes (Appendix B). 
Inclusion criteria were defined for each code to maintain consistency in applying the codebook to 
the interviews.  
  
Complete List of 16 Major Themes  
Theme Number Major Themes 
1 Awareness of Study Purpose  
2 Rationale for Participation  
3 Baseline Cancer Concern 
4 CancerSEEK Emotional Reaction  
5 CancerSEEK Coping  
6 CancerSEEK Process Issue  
7 PET-CT Emotional Reaction  
8 PET-CT Process Issue  
9 PET-CT Incidental Findings  
10 PET-CT Understanding  
11 PET-CT Coping  
12 Emotional Reaction to Discordant Results  
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13 Coping with Discordant Results 
14 Post Results Emotional Response  
15 Previous Cancer Screening (Medical Behavior) 
16 Study Satisfaction  
        Table 1. Complete List of 16 Major Themes.  
 
Software analysis processing issues with Atlas.ti hindered the ability to establish inter-
rater reliability between both coders. Atlas.ti was able to recognize that two individuals were 
coding separately; however, after running an analysis, the software counted the codes as one 
rather than two separate responses. This method would have hindered the overall data analysis; 
therefore, the coders addressed this issue through consensus coding.  
Reliability of the codes was established through an iterative process. Both coders were 
randomly given two interviews to code separately and then compared. This process was repeated 
until both coders were consistently applying the appropriate codes to the themes found in the 
interviews. Once sufficient agreement on the usage of codes was reached, all 36 interviews were 
assessed by both coders together through consensus coding. Interviews were coded at the group 
level, with the intent to capture responses in both the negative and positive PET-CT groups. If a 
participant expressed similar statements multiple times throughout a transcript, the responses 
were repeatedly coded to collectively capture the psychosocial outcomes.    
For the analysis of this study, participants with a negative PET-CT scan for cancer and a 
positive PET-CT scan for cancer were analyzed separately before being compared. Interviews 
from participants in both groups were analyzed for thematic content related to psychosocial 
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outcomes associated with the DETECT study. Comparisons using Atlas.ti were performed 
between and among participants in the positive and negative PET-CT groups.  
Before analysis began, the data were normalized to account for differences in interviews 
of the negative and positive PET-CT participants. More negative PET-CT interviews were 
conducted and the number of coded statements in these interviews was greater than in the 
positive PET-CT interviews. Therefore, code percentages of the positive PET-CTs were 
normalized to account for the difference. The coding percentages for the positive PET-CT 
interviews were multiplied by 1.12, the quotient of the number of negative PET-CT and positive 
PET-CT interviews, 19/17= 1.12. 
Once all interviews were coded, an analysis was run using the “Code Document Table” 
and “Code Co-Occurrence Tree” functions. The results represent significant findings outlined 
within the 16 major themes featured throughout the study, all of which highlight psychosocial 
outcomes associated with a ctDNA-based cancer screening test.   
RESULTS 
Participants 
Eligible participants consisted of 21 individuals with negative follow-up PET-CT scan 
results, of which 19 participated, and 23 individuals with positive follow-up PET-CT scan 
results, of which 17 participated, an overall response rate of 82%. All of the positive PET-CT 
scan interview participants were diagnosed with cancer. Of the eligible women from the 
DETECT study, 3 declined to participate, 1 passed from cancer, 3 could not be reached after five 
phone call attempts and 1 was excluded due to inability to remember participation in the 
DETECT study. Of the study participants, 97% identified as Caucasian. A total of 36 participant 
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interviews were included in the study and subsequently analyzed for psychosocial outcomes 
associated with a ctDNA-based cancer screening test.  
Code Document Table Results  
Awareness of Study Purpose  
In comparing DETECT study awareness among participants, women with negative PET-
CTs were more likely to be aware of the study purpose and less likely to be uninformed of the 
study purpose as compared to women with positive PET-CTs (Figure 1). 
 
 
Figure 1. Study awareness among participants. Abbreviations: Gr=Groundedness of Codes (number of quotations 
attributed to a code), GS= Number of documents in a document group 
 
Rationale for Participation 
In regard to rationale for participation in DETECT among study participants, 40% of the 
overall responses among participants in both groups were coded as altruism. There was no 
significant difference between participants in the negative and positive PET-CT groups. Both 
envisioned their participation to be able to help future generations. Also expressed in about one-
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quarter of responses, in both groups, was a desire to participate because of a family history of 
cancer and a desire to gain more personal health information for personal utility.   
“In order for science or whatever to advance to help people, somebody has to volunteer, and 
I’m glad for other medicines that come up through studies, that I thought well maybe I should 
be the one this time to do the study.” (Negative PET-CT: Altruism) 
 
“Well, I figured that if I could help anyone it would be a plus for people everywhere.” 
(Positive PET-CT: Altruism) 
 
Baseline Cancer Concern 
Among women in the negative PET-CT interview group, the most commonly reported 
emotional response related to “the possibility that the test would lead to finding cancer” was 
acceptance at 46%. This is compared to 50% of responses in the positive PET-CT interview 
group that were unprepared for the possibility that testing would lead to a cancer diagnosis.  
“Cancer was the farthest thing from my mind.” (Positive PET-CT: Unprepared) 
 
“I didn’t think I had any possibility of having any cancer.” (Positive PET-CT: Unprepared) 
 
CancerSEEK Emotional Reaction, Process Issues, and Coping   
Participants mainly reported feelings of surprise and being upset in response to 
CancerSEEK. Participants reported confiding in someone after receiving their CancerSEEK 
blood test result. In both groups, some participants were dissatisfied with the timing and 
communication of study results. 
In the positive PET-CT group, 33% of responses expressed being surprised by the results 
of the CancerSEEK blood test. The most prevalent emotional reaction for the negative PET-CT 
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group were feelings of being upset by the abnormal blood test, which was shared among 20% of 
the overall responses. Of note, 10% of participant responses in the negative PET-CT group 
emphasized feelings of being scared after receiving the CancerSEEK blood test result; however, 
this emotion was not expressed by any participants in the positive PET-CT group.  
Dissatisfaction with timing and communication of DETECT study results was a logistical 
process issue associated with the CancerSEEK blood test. Eight responses by participants in the 
negative PET-CT group and five responses made by participants in the positive PET-CT group 
emphasized these challenges.   
“I wish that [it] could be a shorter period of time so you’re not worrying for weeks and weeks 
about it.” (Negative PET-CT: Dissatisfaction) 
 
“I would think they should be able to process it faster,” (Positive PET-CT: Dissatisfaction) 
 
In regard to coping with the CancerSEEK blood test results, the most prevalent response 
was confiding with family members or close friends. Confiding accounted for 53% of negative 
PET-CTs interview responses and 68% of positive PET-CT interview responses. Of note, 17% of 
negative PET-CT responses for coping expressed relying on the DETECT genetic counselor for 
support; in comparison to positive PET-CT responses with 9%.   
“I talked to a couple of close friends, my husband, my son and daughter… I told them I was 
concerned about it” (Negative PET-CT: Coping - Confiding) 
 
“My significant [other] and my son I did tell, but they were real supportive.” (Positive PET-
CT: Coping - Confiding) 
 
“The counselor, he was very, very helpful and he assured me that, it does not mean I have 
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cancer. ” (Negative PET-CT: Coping - GC) 
 
“The genetic  counselor that called me explained and answered all of my questions, so that 




Figure 2. CancerSEEK coping strategies among participants. Abbreviations: Gr=Groundedness of Codes 
(number of quotations attributed to a code), GS= Number of documents in a document group 
 
PET-CT Emotional Reaction, Process Issues, and Coping  
As with responses to abnormal CancerSEEK blood test results, participants in both 
interview groups coped with the PET-CT results by confiding in others. Of note, the majority of 
positive PET-CT participants reported feeling confused by their results due to unclear result 
disclosure.   
Similarly to the CancerSEEK blood test responses, the most common form of coping 
within the positive PET-CT interview group was confiding in family members or close friends, 
representing 36% of responses. For the negative PET-CT interview group responses, the most 
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common emotional reaction was anxiety, characterized by 36% of responses. Whereas for 
positive PET-CT responses, the most common emotional reaction was acceptance, characterized 
by 26% of responses.   
Sixty percent of positive PET-CT interview responses described participants being 
confused by their results. This confusion was due to participants feeling inadequately informed 
of their results and being overwhelmed by the presented medical language, due to lack of clear 
result disclosure by the clinician. In addition to unclear results, 26% of responses expressed 
dissatisfaction with the timing of result disclosure. Significantly fewer responses in the negative 
PET-CTs interviews, 10%, expressed confusion regarding results. However, significantly more 
of these responses highlight dissatisfaction with the timing of the PET-CT.   
“I have no clarity. I don’t know anything about what this now means, my odds of having 
cancer are or aren’t, and what I might need to be doing other than having the test again.” 
(Positive PET-CT: Confusing Results) 
 
“I couldn’t decipher it all because of course it’s in medical talk.” (Positive PET-CT: 
Confusing Results) 
 
“That’s really scary when you’re waiting 5 and 6 weeks to find out what’s going on. I just had 
to say that. That would be my only complaint.”  (Negative PET-CT: Dissatisfaction) 
 
“They really need to speed this up because it’s just absolutely torture when you know there’s 
something wrong.” (Positive PET-CT: Dissatisfaction)  
 
Psychosocial Reaction to Discordant CancerSEEK Results and PET-CT Findings 
A crucial point of analysis is the psychosocial impact of discordant results for women 
with a false positive CancerSEEK blood test (i.e., positive CancerSEEK with subsequent 
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negative PET-CT scan). For women in the negative PET-CT group, 47% of responses expressed 
relief regarding the non-cancer incidental findings. Another 35% expressed neutral responses, in 
that they had no strong feelings about the non-cancer incidental findings. In comparing how 
women with discordant results coped, 88% of responses stated they confided in someone upon 
receiving the negative PET-CT scan result; while 11% of responses were in reference to relying 
on faith. While being found to be negative for a malignancy, 11 women in the negative PET-CT 
interview group had medically relevant non-cancer incidental findings reported from the PET-
CT scan (e.g., hepatic cysts, pulmonary nodules, thyroid nodules, lung disease, and pericardial 
effusion). Of the six mentions of non-cancer incidental findings among the negative PET-CT 
interview group, five expressed responses of positive emotion regarding the findings.    
“I felt that was OK, you know. Apparently something triggered it, and I’m glad they pursued it 
to make sure everything was OK.” (Negative PET-CT: Relief) 
 
“I’m glad the CT scan didn’t show any tumors at the time.” (Negative PET-CT: Relief) 
 
“I just didn’t get too concerned about it.”  (Negative PET-CT: Neutral) 
 
“I just felt these things happen. I didn’t feel anything different one way or the other.” 
(Negative PET-CT: Neutral)  
 




Figure 3. Emotional reaction to discordant results Negative PET-CT participants. Abbreviations: 
Gr=Groundedness of Codes (number of quotations attributed to a code), GS= Number of documents in a document 
group 
 
Study Satisfaction  
The majority of study participant responses in the negative and positive PET-CT 
interview groups expressed that they would recommend the study to others and supported the 
idea of using the CancerSEEK blood test in routine care. Although anxiety was noted in both 
groups throughout the process, many commented on their appreciation and gratefulness for the 
DETECT study.  
The overwhelming majority of participants expressed responses supporting the use of the 
CancerSEEK blood test in routine care; this sentiment was shared among 94% of responses in 
the negative PET-CT group and 88% of responses in the positive PET-CT group. Remaining 
responses expressed feelings of the DETECT study not yet being ready for use in routine care. 
Similar responses were shared in regard to participants' feelings of whether they would 
recommend the DETECT study to others; this consisted of 100% of responses in the negative 
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PET-CT interview group and 94% of responses in the positive PET-CT interview group. Only 
one response in the positive PET-CT interview group felt they would not recommend the study 
to others. In regard to the overall DETECT study, 20% of positive PET-CT participants (n=3) 
stated that they had a negative DETECT experience. Furthermore, 100% (n=19) of negative 
PET-CT interview participants and 80% (n=14) of positive PET-CT interview participants 
shared that they had a positive DETECT experience.   
Some participants  made  suggestions as to what would make the DETECT study most 
useful in everyday care. Of these stipulations, cost was a major factor for participants in the 
positive PET-CT interview group. Twenty-three percent of responses emphasized that the 
CancerSEEK blood test should be available if it is financially accessible. As well as cost, 33% 
and 15% of negative and positive PET-CT interview responses, respectively, expressed feelings 
that males should be included in the study to have the best impact. The last criteria for inclusion 
participants expressed was that only individuals with a personal or family history should use the 
test in everyday care. This sentiment was expressed by 22% of negative PET-CT interview 
responses compared to 8% of positive PET-CT interview responses. 
“Broaden the study to include not just females but males,” (Negative PET-CT: Include males) 
 
“If it is affordable. I don’t know what the cost is, but it is probably expensive and people who 
don’t have insurance probably, you know, couldn’t do it.” (Positive PET-CT: Cost)   
 
“I think if people have history, family history of it, it would be good for them.” (Positive PET-
CT: Family history) 
 
Regarding participants' emotional reactions to DETECT study satisfaction, in positive 
PET-CT participant interviews, 52% of responses expressed a sense of appreciation and 
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gratefulness for the DETECT study; in comparison to negative PET-CT participant interview 
responses accounting for 24%. Pertaining to negative psychosocial outcomes, 11% of positive 
PET-CT interview responses and 35% of negative PET-CT interview responses reported feelings 
of anxiety throughout the DETECT study. Of note, an important finding from our analysis 
showed that only positive PET-CT participant interview responses expressed feelings of trauma 
or being upset regarding study satisfaction, representing 7% in both categories. 
 
 
Figure 4. Emotional responses regarding study satisfaction among participants. Abbreviations: 
Gr=Groundedness of Codes (number of quotations attributed to a code), GS= Number of documents in a document 
group 
 
“To me, it was a wonderful experience and I was glad to know that if something had come up 
and I would have had to deal with a life or death situation that I wouldn’t stress out about it.” 
 (Negative PET-CT: Positive DETECT Experience) 
 
“I’m grateful something was found and that it didn’t take long to schedule then, the further 
studies, and to move on with a plan.” (Positive PET-CT: Positive DETECT Experience)  
 
 28 
“I’m so grateful to be part of that program and the whole procedure, I’m just very, very 
grateful. It’s something I would have never known about.” (Negative PET-CT: 
Grateful/Appreciation)  
 
“I am grateful that DETECT was there and asked me to participate in this program, because I 
found nothing.” (Positive PET-CT: Grateful/Appreciation)  
 
DISCUSSION  
This qualitative study was performed with the purpose of understanding the psychosocial 
outcomes associated with abnormal ctDNA testing to better understand how it could positively 
or negatively impact patient care. The research performed in this study analyzed participants’ 
emotional reactions and coping strategies, following DETECT study participation, through 
qualitative analysis rather than quantitative measurement. To date, studies of ctDNA for cancer 
detection have primarily been conducted using participants with a cancer diagnosis. The data 
collected from the interviews in this study aids in future understanding of the benefits, 
limitations, and usage of ctDNA-based screening tests in asymptomatic individuals.   
Themes Shared Between Negative and Positive PET-CT Interview Groups 
Between the negative and positive PET-CT interview groups, an overall response rate of 
82% provides evidence of the findings being generalizable across DETECT participants.   
The high percentage of responses supporting the use of the CancerSEEK blood test in 
routine care and the recommendation of DETECT to others, is evidence of the general 
acceptance of the DETECT study among participants, in both interview groups. In regard to 
routine care, 94% of negative PET-CT and 88% of positive PET-CT responses support the usage 
of the CancerSEEK blood test. This result gives support to the benefits of the CancerSEEK blood 
test, outweighing any negative psychosocial outcomes experienced among participants in both 
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groups. Regarding participants’ emotional responses to study satisfaction, both groups 
emphasized finding value in having access to the information and of having a positive outcome 
from participation in the study. This holds true for participants who were given discordant 
CancerSEEK blood test results, suggesting that the discordant results and non-cancer incidental 
findings may not have lasting negative psychosocial impacts.  
While there were certainly positive psychosocial outcomes associated with the 
CancerSEEK blood test found within the study, negative emotions were expressed by 
participants regarding the DETECT study logistics. Both the negative and positive PET-CT 
interview groups responses represented dissatisfaction with the timing and communication of the 
DETECT study results for the CancerSEEK blood test. They had anticipated a shorter wait time 
for return of results and were disappointed by the length of the process. Similar responses of 
dissatisfaction with the timing of result disclosure were expressed regarding the PET-CT scan, 
but a larger number of responses were reported as dissatisfaction with the timing of the PET-CT 
scan procedure. These responses are understandable as women in the DETECT study waited 
weeks to receive results for both the CancerSEEK blood test and PET-CT scan. Responses 
emphasized additional complaints regarding the PET-CT scan procedure and the importance of 
shortening wait times to allow for clear result disclosures in future trials of CancerSEEK.      
Negative PET-CT Interview Themes  
The negative PET-CT interview responses reported a higher percentage of study 
awareness than those in the positive PET-CT interview group. This could be due to these women 
being less overwhelmed by medical care following a cancer diagnosis, or to the anxiety of their 
discordant results, making them hyper-aware of the study purpose. The retrospective nature of 
the study likely created some bias in participant responses based on personal health outcomes, 
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which could explain this result. Participant responses in this group reported feelings of 
acceptance as their most common baseline concern for the possibility of the test detecting cancer. 
Their retrospective acceptance is likely the result of knowing, at the time of the interview, that 
they did not have cancer.   
Feelings of being upset and scared were likely the most common emotional reaction to 
the discordant CancerSEEK blood test because participants were not expecting to receive a 
positive result. Regarding coping with discordant CancerSEEK blood test results, most responses 
reported confiding in a family member or friends. However, responses relying on faith, confiding 
in a GC, and confiding with a non-GC medical professional were all notably higher in the 
negative PET-CT interview group than participants in the positive PET-CT interview group.  
Regarding emotional responses to PET-CT results, it is understandable that the most 
common reaction was nervousness or anxiety. Women in this group may have reported these 
emotions because of the discrepancy between the discordant CancerSEEK blood test and PET-
CT results.  However, this group expressed less confusion after they received their PET-CT scan 
results which provided confirmation that they fully understood that they were not being 
diagnosed with cancer.  The women in this group were subsequently relieved or had no strong 
feelings upon receiving discordant CancerSEEK blood test results and/or non-cancer incidental 
findings. This could mean that there was not a lasting impact of negative psychosocial harms 
following the discordant CancerSEEK blood test results. Notably, all but one of the women in 
this group responded positively towards PET non-cancer incidental findings. This reaction 
towards the PET-CT scan results showed that even if the PET-CT scan did not identify cancer, 
they were grateful that it was capable of identifying other significant findings related to their 
health.   
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Every participant in the negative PET-CT interview group emphasized that they had an 
overall positive DETECT experience. This identification of study satisfaction is helpful for 
future expansion of the DETECT project. Responses in this group reported more feelings of 
anxiety throughout the DETECT study. It is understandable that women in the negative PET-CT 
group emphasized these responses because they received discordant results between the 
CancerSEEK blood test and the PET-CT that led to excessive worry, whereas for the positive 
group any worry would have been justified because they had cancer all along. To highlight 
inclusion criteria, more responses in the negative PET-CT interview group expressed that only 
individuals with a personal or family history of cancer should use the test in everyday care. This 
response may be emphasizing that utilizing average-risk individuals in cancer screening studies 
can result in negative psychosocial harms due to excessive worry.         
Positive PET-CT Interview Themes  
The increased lack of study awareness among women in the positive PET-CT interview 
group was an interesting finding. These women may have been overwhelmed by the medical 
care received after their cancer diagnosis, and less aware of the DETECT study as the reason for 
that diagnosis. This was surprising given that cancer had been diagnosed through study 
participation.  It was assumed that more of these women would be aware of the DETECT study 
purpose.  
Again, the retrospective nature of the study and the final health outcome of a cancer 
diagnosis may have created some recall bias among responses. In regard to baseline cancer 
concern before starting the study, it is understandable that the majority of responses by women in 
the positive PET-CT interview group had not considered the possibility of developing cancer. 
Had these women not been diagnosed with cancer, it is possible that they, retrospectively, would 
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have had more accepting responses towards that outcome. This sentiment is also seen in the 
responses of women in this group towards the results of the CancerSEEK blood test. Women 
were likely accepting of the result because with the benefit of hindsight they knew the results of 
the CancerSEEK test to be true.  
This study highlighted the importance of having a support system in place. Over half of 
the responses to coping with results of the CancerSEEK blood test in the positive PET-CT group 
expressed confiding in family or close friends; in addition, one-third of responses in this group 
also expressed confiding as a way of coping with the results of the PET-CT scan. This shows that 
like other cancer screenings, people want to share their results with those they are close to for 
support. But it is interesting to note that many women in this group also internalized the results, 
not wanting to share until they had more information. This could be the result of not having a 
strong support system or needing confirmation before worrying others. 
It is important to note the significant differences in responses in the positive PET-CT 
interview group that expressed being confused by the results of their PET-CT scan compared to 
those with negative PET-CT results. It is presumed that this confusion was due in part to 
participants feeling inadequately informed of their results and being overwhelmed by the medical 
language used. Clinicians can better communicate next steps, when a PET-CT is abnormal, by 
disclosing results in-person and having a GC present to help define complicated medical 
terminology. The presence of a GC would likely help alleviate the confusion and unclear results. 
In addition to confusing results, responses expressed dissatisfaction with wait time for disclosure 
of results; so much so that some women expressed discovering their cancer diagnosis by means 
outside of the study. In thinking about the routine use of the CancerSEEK blood test and the 
DETECT protocol, there is a need to address the time it takes for results to be released to patients 
 33 
as well as how these results are communicated. Hence, the next trial of the DETECT study 
should help to address these issues. 
It was postulated that there could be negative psychosocial outcomes for asymptomatic 
women in the study to be diagnosed with cancer, but the lack of responses regarding feelings of 
being upset or traumatized throughout study participation aids in disputing this thought. In 
contrast, responses in the positive PET-CT interview group expressed more positive 
psychosocial outcomes from study participation such as gratefulness and appreciation for being 
in the study.  Women were grateful and appreciated participating in the study despite lacking the 
same level of study awareness of DETECT as participants in the negative PET-CT interview 
group. Responses expressed feelings of finding value in the information, given that the 
knowledge was used to make medically actionable decisions. It is reassuring for the possible 
future use of the CancerSEEK blood test that, among responses in this group, there was 
pervasive acceptance for routine use of the test and sentiments stating that participants would 
recommend the study to others.  
Study Limitations  
While the study was designed to capture the range of psychosocial experiences and be 
generalizable to larger populations, there are limitations of this study. While we maintain that the 
sample size of the study was appropriate for the type of research performed, because a saturation 
of themes was reached, studies in different populations (e.g., those with men or more racial 
diversity) could present different psychosocial themes. Furthermore, the sample size consisted of 
a comparison of responses for only two interview groups, the negative and positive PET-CTs for 
cancer. Further research is warranted to investigate the psychosocial outcomes of individuals 
with non-cancer incidental findings who are negative for cancer. 
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It is recognized as a study limitation that the length of the DETECT study process likely 
impacted recall, making it difficult for study participants to separate the CancerSEEK blood test 
results from the abnormal, or normal PET-CT scan responses. Also, the retrospective design is a 
limitation of the study. Participant responses were likely biased based on their personal health 
outcomes in the study. A future study to address this limitation could be designed using a pre-
post test qualitative or quantitative approach, in which participants’ baseline psychosocial state 
was captured prior to study intervention and diagnosis. Lastly, this study does not compare 
psychosocial outcomes of ctDNA cancer screening to currently utilized screening methods. A 
future study could compare outcomes in participants with discordant CancerSEEK blood test 
results to those with discordant results from routine cancer screenings such as mammography.  
CONCLUSIONS 
The goal of our study was to assess psychosocial outcomes associated with a ctDNA-based 
cancer screening test, by questioning whether the CancerSEEK blood test was acceptable to 
women with an abnormal result. It is clear from our analysis that distinct similarities and 
differences exist between the negative and positive PET-CT interview groups, highlighting the   
psychosocial outcomes. The results that most significantly informed psychosocial outcomes of 
CancerSEEK include: 
1. Most notably, the majority of responses in both groups reported having a positive 
experience with the DETECT study and would recommend it to others. This is especially 
important to note for the negative PET-CT participants who received discordant 
CancerSEEK blood test results. 
2. Among all responses in both groups, confiding in family and friends was the most 
commonly utilized coping strategy, following the results of the CancerSEEK blood test. 
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This emphasized the importance of a sufficient support system being available following 
screening.  
3. For participants in the negative PET-CT group, who received non-cancer incidental 
findings, the most prevalent emotional response was relief about the findings. While 
anxiety was expressed regarding the false positive blood test, participants appreciated the 
knowledge of the non-cancer incidental findings.  
4. Among responses in both groups, there was expression of dissatisfaction with the 
turnaround time for the CancerSEEK blood test and PET-CT results and the method in 
which these results were communicated. Issues surrounding result disclosure was a 
source of anxiety and concern based on study responses and needs to be further reviewed  
for an effective screening protocol.     
While this research is reassuring in providing evidence of the acceptability of the 
CancerSEEK blood test as a screening method among those with an abnormal CancerSEEK 
result, continued research should be explored to expand on these findings and identify additional 
potential benefits of ctDNA testing. It is the hope that one day, a ctDNA cancer screen will be 
implemented for early detection of cancer, particularly for those cancers without valid screening 
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Qualitative Interview Guide 
[Introduction Script] Hello, Ms._______. My name is Gabby/Simone and I’m a Genetic 
Counseling Student working with Geisinger Health System. I am calling about the DETECT 
study that you are part of. We would like to know more about your experiences with the study. 
Would you be interested in answering some questions about your participation in the study? 
[If no] Is there another time you would be available and interested in participating? 
[If yes, discuss new time for interview and plan to re-contact the patient.]   
[If no] Thank you for your time and thanks again for being in DETECT. 
[If yes] These questions should take up to 15-20 minutes. Do you have time to answer them 
now? 
[If yes] Thank you. Before we start, here are a couple of things to know about this interview. We 
are interviewing DETECT participants who had an abnormal result on the DETECT blood test. 
Your responses will help us learn more about what it is like to receive a result like yours. I will 
ask you some broad questions and then follow-up with some more specific questions about your 
experience with receiving results from the DETECT study. You can say whatever you want – 
nothing will hurt my feelings and nothing you say will have a negative effect on your care. 
Everything you tell me will be kept confidential. Your interview responses will only be shared 
with research team members and nothing will identify you if the information you share is used 
for future reports on the findings from this study. Participation in this interview is voluntary and 
you can stop at any time. Please remember: be honest with your responses and you do not have 
to answer anything you do not want to talk about. You can end the interview at any time. If you 
have any questions you can ask us during the interview or contact us afterwards at the following 
phone numbers: (570) 301-3014 or (336) 254-8378. Do you have any questions about this 
interview? Do you agree to participate in this study? 
[If yes to participation] Before we begin, would you mind if I recorded this conversation so that 
I make sure I don’t miss anything that you tell me? We will remove your name and any 
identifying information from the recording. Some of this information will be stored in a research 
record at Geisinger and they can be kept for up to 3 years. 
[If no to participation] Thank you for your time and thanks again for being in DETECT. 
[If no to recording] Okay, that’s fine. I may need a little bit of extra time to make sure I write 
down what you tell me as completely as possible. 
1) Do you remember why the DETECT study is being done?   
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[If yes] Can you tell me in your own words why they are doing the DETECT study? 
[If no] The DETECT study uses a blood sample to look for cancer markers, either DNA from a 
tumor or elevated levels of proteins.  You may recall having your blood drawn after consenting 
to be part of the project. The purpose of the DETECT study is to learn how well the blood test 
works at finding cancer early.  
2) What motivated you to want to join the study?  
        1. Probe (if applies):  What did you hope to get from being in the study? 
        2. Probe (if applies):  Some participants expressed that they have a strong family history of 
cancer and maybe by participating in this study they might better understand their own cancer 
risk. Was this the case for you? 
         3. Probe: Others my may want to help further scientific research and see if this technology 
can be helpful to future generations. Was this the case for you? 
         4. Probe (if applies): *If more than one motivation listed ask* “which one influenced you 
the most?” 
3) When you joined the study, how did you feel about the possibility that the test would lead to 
finding cancer? 
    Narrative:  We know that when someone is diagnosed with cancer, genetic material known 
as DNA is shed into their bloodstream.  This specific type of genetic material is called 
circulating tumor DNA or ctDNA. As you recall, ctDNA or biomarkers looking for these 
specific cancers were detected in your bloodstream when we looked at your sample. This 
result did not necessarily mean that you had cancer, so the study team recommended that 
you have additional testing with a PET-CT scan. 
4) How did you feel when the blood work results were abnormal indicating the possible presence 
of cancer? 
   1. Probe (if applies): Was this type of result something you were expecting?  
   2. Probe (if applies): Emotionally and psychologically, what did you experience after 
getting these results? 
   3. Probe: How did you feel about being asked to have a PET-CT scan? 
   4. Probe (if applies): Who did you lean on and communicate these results to?  
 41 
      5. Probe: Did you find that you needed more support than expected after receiving the 
results?   
5) (For abnormal PET-CT scan) What do you remember about the results of the PET-CT scan? 
    1. Probe (if applies): What did you do medically to follow-up on the scan?     
      2. Probe (if applies):  How did you feel about the results of the PET-CT scan? 
   3. Probe (if applies): Was this type of result something you were expecting?  
   4. Probe (if applies): Emotionally and psychologically, what did you experience after 
getting these results? 
        5. Probe (if applies): How are you dealing with a cancer diagnosis? 
        6. Probe (if applies): Does this result change any future management for you going 
forward? 
     7. Probe (if applies): Who did you communicate these results to? 
        8. Probe (if applies): Who did you lean on for emotional support? 
     9. Probe (if applies): Did you need more support than expected? 
6) (For normal PET-CT scan) What do you remember about the results of the PET-CT scan? 
     1. Probe (if applies): What did you do medically to follow-up on the scan? 
              2. Probe (if applies): How did you feel about having an abnormal blood test but normal 
PET-CT scan? 
     3. Probe (if applies): Was this type of result something you were expecting?  
        4. Probe (if applies): Emotionally and psychologically, what did you experience after 
getting these results? 
     5. Probe (if applies): Who did you communicate these results to? 
     6. Probe (if applies): Who did you lean on for emotional support? 
     7. Probe (if applies): Did you need more support than expected? 
7) How have your feelings toward the DETECT study changed since you received your PET-CT 
scan results?   
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        1. Probe (if applies): [If yes] How?  
        2. Probe (if applies): [If no] Can you tell me more about why you did not feel any 
different about the DETECT study? 
        3. Probe: Would you recommend to friends or family members that they join DETECT? 
8) How did cancer screening in this study compare to other cancer screening you have done? 
        1. Probe (if applies): What cancer screening do you routinely have?  
9) What are your thoughts on whether the DETECT blood test should be part of everyday care?  
         1. Probe (if test should be part of everyday care): Before the test were offered in 
everyday care, what would you change about how the test is performed or followed up on?  
         2. Probe (if not ready for everyday care): What else needs to be done or studied before 
the test is ready for everyday care? 
10) What other psychological, emotional or social outcomes from your participation in the study 
would you like to share? 
Conclusion:  Those are all of the questions I have.  Thank you for your participation in this 
interview. I appreciate your time and responses. Your answers will help to better understand the 
expectations and experiences of study participants and may help improve how to better 
understand DETECT study results. Your responses will remain confidential. If you have any 














The Complete List of 76 Codes 
Code Number Major Themes - Code Definition/Inclusion Criteria 
1 Awareness of Study Purpose - 
Knowledgeable  
Participant was actively able to recognize the 
purpose of the DETECT study  
2 Awareness of Study Purpose- 
Uninformed 
Participant was not actively able to recognize the 
purpose of the DETECT study 
3 Rationale for Participation - Altruism  Participant used statement of wanting to help others 
and contribute to the current body of scientific 
research, including early cancer detection 
4 Rationale for Participation - Family 
History 
Participant used statement of family history of 
cancer 
5 Rationale for Participation - Personal 
Utility 
Participant wanted to know the information for their 
own health; early detection 
6 Rationale for Participation - Unsure Participant was not aware of a specific reason for 
enrollment 
7 Rationale for Participation - Cure Participant joined DETECT in the hope of finding a 
cure for cancer  
8 Baseline Cancer Concern - Unprepared Participant did not think about the possibility of 
cancer 
9 Baseline Cancer Concern - 
Unconcerned/Not worried 
Participant was not concerned about the possible 
thought of cancer 
10 Baseline Cancer Concern - Acceptance Participant applied statements of acceptance 
regarding cancer recognition  
11 Baseline Cancer Concern - Distress  Participant felt upset, nervous, or anxious regarding 
the idea of cancer detection  
12 Baseline Cancer Concern - Scared Participant felt scared to learn about new 
information regarding a potential cancer diagnosis 
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13 CancerSEEK Emotional Reaction - 
Anxiety 
Use when participant verbalizes statements of 
anxiety  
14 CancerSEEK Emotional Reaction - 
Upset 
Use when participant verbalizes statements of being 
upset 
15 CancerSEEK Emotional Reaction - 
Concern 
Use when participant verbalizes statements of 
concern 
16 CancerSEEK Emotional Reaction - 
Scared 
Use when participant verbalizes statements of being 
scared 
17 CancerSEEK Emotional Reaction - 
Acceptance 
Use when participant verbalizes statements of 
acceptance 
18 CancerSEEK Emotional Reaction - 
Confusion 
Use when participant verbalizes statements of 
confusion 
19 CancerSEEK Emotional Reaction - 
Surprise 
Use when participant verbalizes statements of not 
expecting result 
20 CancerSEEK Emotional Reaction - 
Not surprised/Not worried 
Use when participant verbalizes that the results did 
not have a significant impact on their quality of life  
21 CancerSEEK Emotional Reaction - 
Control group 
Use when participant verbalizes belief that they 
belonged to a different group within the study  
22 CancerSEEK Coping - Internalized  Use when participant verbalizes that they dealt with 
results alone; did not communicate 
23 CancerSEEK Coping - Confiding Use when participant verbalizes that they dealt with 
result by confiding in someone 
24 CancerSEEK Coping –  
Genetic Counselor  
Use when participant expresses communication, 
reliance, or reassurance with a genetic counselor 
25 CancerSEEK Coping – Non-GC 
Medical Professional 
Use when participant verbalizes concern with a 
different medical professional other than a GC, 
relied on gaining information and communicating a 
with doctor 
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26 CancerSEEK Coping - 
Faith 
Use when participant verbalizes that they relied on 
faith and prayer 
27 CancerSEEK Process Issue - 
Dissatisfaction 
Use when participant verbalizes statements of being 
dissatisfied with timing of results for CancerSEEK  
28 PET-CT Emotional Reaction - Upset  Participant expresses statements of feeling upset 
29 PET-CT Emotional Reaction - 
Concerned 
Participant expresses statements of concern  
30 PET-CT Emotional Reaction - Not 
Concerned 
Participant expresses statements of no concern  
31 PET-CT Emotional Reaction - 
Acceptance 
Participant expresses statements of acceptance  
32 PET-CT Emotional Reaction - Not 
Expecting Results 
Participant expresses statements of not expecting 
results 
33 PET-CT Emotional Reaction - Relief Participant expresses relief after positive PET-CT 
results 
34 PET-CT Emotional Reaction - 
Nervousness/Anxiety  
Participant expresses statements of 
nervousness/anxiety 
35 PET-CT Process Issue - Dissatisfaction  Participant expresses statements of being 
dissatisfied with the timing and communication of 
results for the PET-CT scan   
36 PET-CT Process Issue - PCP 
Communication 
Participant expresses problems reaching PCP after 
disclosure of PET-CT results 
37 PET-CT Non-Cancer Incidental 
Findings - Positive Response to Non-
Cancer Incidental Findings 
Participant expresses positive emotion regarding 
secondary findings  
38 PET-CT Non-Cancer Incidental 
Findings - Negative Response to Non-
Cancer Incidental Findings 
Participant expresses negative emotion regarding 
secondary findings  
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39 PET-CT Understanding - Confusing 
Results 
Participant expresses statements of lack of 
understanding regarding the meaning of results 
40 PET-CT Coping - Faith  Participant expresses they relied on faith and prayer 
41 PET-CT Coping - Confiding Use when participant verbalizes that they dealt with 
result by confiding in someone 
42 Emotional Reaction to Discordant 
Results - Relief/Reassurance 
Participant expresses relief after disclosure of 
results 
43 Emotional Reaction to Discordant 
Results - Frustration 
Participant expresses frustration that bloodwork was 
abnormal and PET-CT was normal  
44 Emotional Reaction to Discordant 
Results - Concern 
Participant expresses concern with the discordant 
results 
45 Emotional Reaction to Discordant 
Results - Neutral 
Participant expresses no strong emotions negatively 
or positively 
46 Coping with Discordant Results - 
Confiding 
Participant expresses that they dealt with discordant 
results by confiding in someone 
47 Coping with Discordant Results - Faith Participant expresses coping with discordant results 
by relying on faith and prayer  
48 Post Results Emotional Response - 
Scared 
Participant expressed statements of being scared 
following participation 
49 Post Results Emotional Response - 
Self-Guilt 
Participant expressed statements of guilt for poor 
personal habits 
50 Post Results Emotional Response - 
Importance of Medical Care 
Participant expressed statements of being more 
vigilant of medical needs/care 
51 Previous Cancer Screening (Medical 
Behavior) - Similar Screening 
Comparison 
Participant verbalized that previous cancer 
screening is comparable to other cancer screenings 
or no different  
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52 Previous Cancer Screening (Medical 
Behavior) - Different Screening 
Comparison 
Participant verbalized that previous cancer 
screening is non-comparable to other cancer 
screenings 
53 Previous Cancer Screening (Medical 
Behavior) - Ease of Process 
Participant verbalized that the PET-CT and entire 
DETECT process was easier than other screenings  
54 Previous Cancer Screening (Medical 
Behavior) - Inconvenient 
Participant verbalized that cancer screening through 
DETECT is inconvenient/time consuming than 
other screenings 
55 Previous Cancer Screening (Medical 
Behavior) - Comprehensive 
Participant verbalized that cancer screening through 
DETECT is more in depth than other cancer 
screenings 
56 Study Satisfaction - Include Males Participant felt the inclusion criteria should have 
included males  
57 Study Satisfaction - Personal/Family 
History 
Participant felt that the study is useful if participant 
has an extensive medical/family history  
58 Study Satisfaction - Cost Participant verbalized that DETECT is useful if 
offered at the appropriate cost 
59 Study Satisfaction - Study Outcomes Participant verbalized that DETECT is useful based 
on overall study outcomes 
60 Study Satisfaction - Prevention Participant verbalized that DETECT is useful for 
prevention 
61 Study Satisfaction - Positive DETECT 
Experience 
Participant verbalized overall positive statements 
towards DETECT and the study process 
62 Study Satisfaction - Negative 
DETECT Experience 
Participant verbalized overall negative statements 
towards DETECT and the study process 
63 Study Satisfaction - Use in Routine 
Care 
Participant thinks DETECT should be used in 
routine care 
64 Study Satisfaction - Not used in 
Routine Care 
Participant does not think DETECT should be used 
in routine care  
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65 Study Satisfaction - Ease of Process Participant felt the process for DETECT was easier 
than other screenings/simple way to detect cancers 
early  
66 Study Satisfaction - Access to 
Information  
Participant valued having access to the information 
67 Study Satisfaction - Anxiety Participant felt that parts of the process caused 
anxiety 
68 Study Satisfaction - Upset  Participant verbalized statements of feeling upset 
69 Study Satisfaction - Traumatic Participant verbalized being emotionally 
traumatized from the experience 
70 Study Satisfaction - Change in 
Feelings 
Participant expressed change in attitude towards the 
study 
71 Study Satisfaction - No Change in 
Feelings 
Participant did not express change in attitude 
towards the study 
72 Study Satisfaction - 
Grateful/Appreciation 
Participant expressed statements of appreciation for 
study and getting results 
73 Study Satisfaction - Recommend to 
Others 
Participant would recommend the DETECT study 
to others 
74 Study Satisfaction - Not Recommend 
to Others 
Participant would not recommend the DETECT 
study to others 
75 Study Satisfaction - Positive Outcomes Participant expressed statements of positive 
experiences with medical professionals, rather than 
experiences with the DETECT project  














Gr=348;  GS=19 
 




● Awareness of study purpose - Knowledgeable 
Gr=21 12 3.43% 
● Awareness of study purpose- Uninformed 
Gr=15 
7 2.00% 
● Baseline Cancer Concern - Acceptance 
Gr=19 
11 3.14% 
● Baseline Cancer Concern - Distress 
Gr=2 2 0.57% 
● Baseline Cancer Concern - Scared 
Gr=1 1 0.29% 
● Baseline Cancer Concern - Unconcerned/Not worried 
Gr=8 
6 1.71% 
● Baseline Cancer Concern - Unprepared 
Gr=14 
4 1.14% 
● CancerSEEK Coping - Confiding 
Gr=31 
16 4.57% 
● CancerSEEK Coping - Faith 
Gr=6 5 1.43% 
● CancerSEEK Coping - GC 
Gr=7 5 1.43% 
● CancerSEEK Coping - Internalized 
Gr=4 
1 0.29% 
● CancerSEEK Coping - non-GC Medical professional 
Gr=4 
3 0.86% 
● CancerSEEK emotional reaction - Acceptance 
Gr=20 7 2.00% 
● CancerSEEK emotional reaction - Anxiety 
Gr=6 5 1.43% 
● CancerSEEK emotional reaction - Concern 
Gr=10 7 2.00% 
● CancerSEEK emotional reaction - Confusion 
Gr=1 
0 0.00% 
● CancerSEEK emotional reaction - Control group 
Gr=1 
0 0.00% 
● CancerSEEK emotional reaction - Not surprised/Not worried 
Gr=6 3 0.86% 
● CancerSEEK emotional reaction - Scared 
Gr=4 4 1.14% 
● CancerSEEK emotional reaction - Surprise 
Gr=18 6 1.71% 
● CancerSEEK emotional reaction - Upset 
Gr=10 
8 2.29% 




● Coping with discordant results - Confiding 
Gr=17 15 4.29% 
● Coping with discordant results - Faith 
Gr=2 2 0.57% 
● Emotional reaction to discordant results - Concern 
Gr=1 1 0.29% 
● Emotional reaction to discordant results - Frustration 
Gr=2 
2 0.57% 
● Emotional reaction to discordant results - Neutral 
Gr=6 
6 1.71% 
● Emotional reaction to discordant results - Relief/Reassurance 
Gr=8 8 2.29% 
○ PET-CT coping - Confiding 
Gr=11 0 0.00% 
● PET-CT Coping - Faith 
Gr=3 
3 0.86% 
● PET-CT emotional reaction - Acceptance 
Gr=13 
5 1.43% 
● PET-CT emotional reaction - Concerned 
Gr=2 2 0.57% 
● PET-CT emotional reaction - Nervousness/anxiety 
Gr=8 8 2.29% 
● PET-CT emotional reaction - Not concerned 
Gr=6 3 0.86% 
● PET-CT emotional reaction - Not expecting results 
Gr=3 
1 0.29% 
○ PET-CT emotional reaction - Relief/Reassurance 
Gr=3 
0 0.00% 
● PET-CT emotional reaction - Upset 
Gr=3 0 0.00% 
● PET-CT Process Issue - Dissatisfaction 
Gr=17 13 3.71% 
● PET-CT Process Issue - PCP communication 
Gr=7 5 1.43% 
● PET-CT Understanding - Confusing results 
Gr=11 
2 0.57% 
● PET-CT Non-Cancer incidental findings - Negative response to Non-
Cancer incidental findings 
Gr=1 
1 0.29% 




● Post results emotional response - Importance of medical care 
Gr=1 
0 0.00% 
● Post results emotional response - Scared 
Gr=1 
0 0.00% 
● Post results emotional response - Self-guilt 
Gr=2 2 0.57% 
● Previous Cancer Screening (Medical Behavior) - Comprehensive 
Gr=8 2 0.57% 








● Previous Cancer Screening (Medical Behavior) - Inconvenient 
Gr=4 3 0.86% 




● Rationale for participation - Altruism 
Gr=25 
13 3.71% 
● Rationale for participation - Cure 
Gr=3 
3 0.86% 
● Rationale for participation - Family history 
Gr=16 9 2.57% 
● Rationale for participation - Personal utility 
Gr=14 7 2.00% 
● Rationale for participation - Unsure 
Gr=5 1 0.29% 
● Study satisfaction -  Study outcomes 
Gr=1 
1 0.29% 
● Study satisfaction - Anxiety 
Gr=9 
6 1.71% 
● Study satisfaction - Change in feelings 
Gr=1 1 0.29% 
● Study satisfaction - Cost 
Gr=3 0 0.00% 
● Study satisfaction - Ease of process 
Gr=3 
0 0.00% 
● Study satisfaction - Access to information 
Gr=7 
4 1.14% 
● Study satisfaction - Grateful/appreciation 
Gr=18 4 1.14% 
● Study satisfaction - Include males 
Gr=5 3 0.86% 
● Study satisfaction - Lack of care 
Gr=3 0 0.00% 
● Study satisfaction - Negative DETECT experience 
Gr=5 
0 0.00% 
● Study satisfaction - No change in feelings 
Gr=29 
20 5.71% 
● Study satisfaction - Not recommend to others 
Gr=1 0 0.00% 
● Study satisfaction - Not used in routine care 
Gr=3 1 0.29% 
● Study satisfaction - Personal/family history 
Gr=3 2 0.57% 
● Study satisfaction - Positive DETECT experience 
Gr=33 
13 3.71% 
● Study satisfaction - Positive outcomes 
Gr=6 
3 0.86% 
● Study satisfaction - Prevention 
Gr=5 4 1.14% 
● Study satisfaction - Recommend to others 
Gr=33 17 4.86% 
● Study satisfaction - Traumatic 
Gr=2 0 0.00% 




● Study satisfaction - Use in routine care 
Gr=31 16 4.57% 














































Gr=313;  GS=17 
 




● Awareness of study purpose - Knowledgeable 
Gr=21 9 2.96% 
● Awareness of study purpose- Uninformed 
Gr=15 
8 2.63% 
● Baseline Cancer Concern - Acceptance 
Gr=19 
8 2.63% 
● Baseline Cancer Concern - Distress 
Gr=2 0 0.00% 
● Baseline Cancer Concern - Scared 
Gr=1 0 0.00% 
● Baseline Cancer Concern - Unconcerned/Not worried 
Gr=8 
2 0.66% 
● Baseline Cancer Concern - Unprepared 
Gr=14 
10 3.29% 
● CancerSEEK Coping - Confiding 
Gr=31 
15 4.93% 
● CancerSEEK Coping - Faith 
Gr=6 1 0.33% 
● CancerSEEK Coping - GC 
Gr=7 2 0.66% 
● CancerSEEK Coping - Internalized 
Gr=4 
3 0.99% 
● CancerSEEK Coping - non-GC Medical professional 
Gr=4 
1 0.33% 
● CancerSEEK emotional reaction - Acceptance 
Gr=20 13 4.28% 
● CancerSEEK emotional reaction - Anxiety 
Gr=6 1 0.33% 
● CancerSEEK emotional reaction - Concern 
Gr=10 3 0.99% 
● CancerSEEK emotional reaction - Confusion 
Gr=1 
1 0.33% 
● CancerSEEK emotional reaction - Control group 
Gr=1 
1 0.33% 
● CancerSEEK emotional reaction - Not surprised/Not worried 
Gr=6 3 0.99% 
● CancerSEEK emotional reaction - Scared 
Gr=4 0 0.00% 
● CancerSEEK emotional reaction - Surprise 
Gr=18 12 3.95% 
● CancerSEEK emotional reaction - Upset 
Gr=10 
2 0.66% 




● Coping with discordant results - Confiding 
Gr=17 2 0.66% 
● Coping with discordant results - Faith 
Gr=2 0 0.00% 
● Emotional reaction to discordant results - Concern 
Gr=1 0 0.00% 
● Emotional reaction to discordant results - Frustration 
Gr=2 
0 0.00% 
● Emotional reaction to discordant results - Neutral 
Gr=6 
0 0.00% 
● Emotional reaction to discordant results - Relief/Reassurance 
Gr=8 0 0.00% 
○ PET-CT coping - Confiding 
Gr=11 11 3.62% 
● PET-CT Coping - Faith 
Gr=3 
0 0.00% 
● PET-CT emotional reaction - Acceptance 
Gr=13 
8 2.63% 
● PET-CT emotional reaction - Concerned 
Gr=2 0 0.00% 
● PET-CT emotional reaction - Nervousness/anxiety 
Gr=8 0 0.00% 
● PET-CT emotional reaction - No recall of PET-CT 
Gr=0 0 0.00% 
● PET-CT emotional reaction - Not concerned 
Gr=6 
3 0.99% 
● PET-CT emotional reaction - Not expecting results 
Gr=3 
2 0.66% 
○ PET-CT emotional reaction - Relief/Reassurance 
Gr=3 3 0.99% 
● PET-CT emotional reaction - Upset 
Gr=3 3 0.99% 
● PET-CT Process Issue - Dissatisfaction 
Gr=17 4 1.32% 
● PET-CT Process Issue - PCP communication 
Gr=7 
2 0.66% 
● PET-CT Understanding - Confusing results 
Gr=11 
9 2.96% 
● PET-CT Non-Cancer incidental findings - Negative response to Non-
Cancer incidental findings 
Gr=1 
0 0.00% 




● Post results emotional response - Importance of medical care 
Gr=1 
1 0.33% 
● Post results emotional response - Scared 
Gr=1 1 0.33% 
● Post results emotional response - Self-guilt 
Gr=2 0 0.00% 
● Previous Cancer Screening (Medical Behavior) - Comprehensive 
Gr=8 6 1.97% 





● Previous Cancer Screening (Medical Behavior) - Ease of process 
Gr=3 2 0.66% 
● Previous Cancer Screening (Medical Behavior) - Inconvenient 
Gr=4 1 0.33% 




● Rationale for participation - Altruism 
Gr=25 
12 3.95% 
● Rationale for participation - Cure 
Gr=3 0 0.00% 
● Rationale for participation - Family history 
Gr=16 7 2.30% 
● Rationale for participation - For a lost friend or significant other 
Gr=0 0 0.00% 
● Rationale for participation - Personal utility 
Gr=14 
7 2.30% 
● Rationale for participation - Unsure 
Gr=5 
4 1.32% 
● Study satisfaction -  Study outcomes 
Gr=1 0 0.00% 
● Study satisfaction - Anxiety 
Gr=9 3 0.99% 
● Study satisfaction - Change in feelings 
Gr=1 
0 0.00% 
● Study satisfaction - Cost 
Gr=3 
3 0.99% 
● Study satisfaction - Ease of process 
Gr=3 3 0.99% 
● Study satisfaction - Access to information  
Gr=7 3 0.99% 
● Study satisfaction - Grateful/appreciation 
Gr=18 14 4.61% 
● Study satisfaction - Include males 
Gr=5 
2 0.66% 
● Study satisfaction - Lack of care 
Gr=3 
3 0.99% 
● Study satisfaction - Negative DETECT experience 
Gr=5 5 1.65% 
● Study satisfaction - No change in feelings 
Gr=29 9 2.96% 
● Study satisfaction - Not recommend to others 
Gr=1 1 0.33% 
● Study satisfaction - Not used in routine care 
Gr=3 
2 0.66% 
● Study satisfaction - Personal/family history 
Gr=3 
1 0.33% 
● Study satisfaction - Positive DETECT experience 
Gr=33 20 6.58% 
● Study satisfaction - Positive outcomes 
Gr=6 3 0.99% 
● Study satisfaction - Prevention 
Gr=5 1 0.33% 




● Study satisfaction - Regrets participation 
Gr=0 0 0.00% 
● Study satisfaction - Traumatic 
Gr=2 2 0.66% 
● Study satisfaction - Upset 
Gr=2 2 0.66% 
● Study satisfaction - Use in routine care 
Gr=31 
15 4.93% 
Totals 304 100.00% 
 
 
 
 
 
